Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma

X
Trial Profile

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cevostamab (Primary) ; Steroids; Tocilizumab
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 12 Dec 2023 Results of integrative analysis of peripheral blood (PB) and bone marrow aspirate (BMA) samples collected at baseline from patients in this study to understand the heterogeneity of patients with RRMM and potential correlations with clinical outcome, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (N=310, At data cut-off (March 1, 2023)) assessing whether responders in the GO39775 study demonstrated evidence of immune reconstitution (IR) while on cevostamab therapy, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 15 Jun 2023 Results (At cut-off (August 22, 2022, n= 75 ) presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top